|
Real-time Estimate
Cboe BZX
10:41:04 2026-10-29 EDT
|
5-day change | 1st Jan Change | ||
| 290.66 USD | +1.63% |
|
+2.00% | +27.31% |
| 10:39am | Eli Lilly, Merck Third-Quarter Results Top Street Views | MT |
| 10:04am | Swiss biotech firm Molecular Partners to cut nearly half of workforce | RE |
Company Valuation: AbbVie Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 239,371 | 285,707 | 273,605 | 314,021 | 403,830 | 505,378 | - | - |
| Change | - | 19.36% | -4.24% | 14.77% | 28.6% | 25.15% | - | - |
| Enterprise Value (EV) 1 | 306,225 | 339,749 | 320,176 | 375,610 | 463,570 | 567,227 | 559,646 | 547,558 |
| Change | - | 10.95% | -5.76% | 17.31% | 23.42% | 22.36% | -1.34% | -2.16% |
| P/E | 21x | 24.4x | 57x | 74.4x | 96.8x | 37.4x | 27.3x | 22.5x |
| PBR | 15.5x | 16.6x | 26.5x | 94.8x | -124x | -81.6x | -329x | 52.7x |
| PEG | - | 8.74x | -1x | -6.1x | -77.12x | 0x | 0.7x | 1x |
| Capitalization / Revenue | 4.27x | 4.92x | 5.04x | 5.57x | 6.6x | 7.47x | 6.87x | 6.38x |
| EV / Revenue | 5.46x | 5.85x | 5.89x | 6.67x | 7.58x | 8.39x | 7.61x | 6.91x |
| EV / EBITDA | 10.6x | 11x | 12.5x | 15.6x | 18.9x | 17.4x | 15x | 13.2x |
| EV / EBIT | 10.9x | 11.3x | 12.9x | 16.1x | 19.5x | 18.1x | 15.5x | 13.7x |
| EV / FCF | 13.9x | 14x | 14.5x | 21.1x | 26x | 21.4x | 15.3x | 14.8x |
| FCF Yield | 7.18% | 7.14% | 6.89% | 4.75% | 3.84% | 4.67% | 6.54% | 6.74% |
| Dividend per Share 2 | 5.31 | 5.71 | 5.99 | 6.29 | 6.65 | 6.876 | 7.254 | 7.562 |
| Rate of return | 3.92% | 3.53% | 3.87% | 3.54% | 2.91% | 2.4% | 2.54% | 2.64% |
| EPS 2 | 6.45 | 6.63 | 2.72 | 2.39 | 2.36 | 7.647 | 10.46 | 12.71 |
| Distribution rate | 82.3% | 86.1% | 220% | 263% | 282% | 89.9% | 69.3% | 59.5% |
| Net sales 1 | 56,122 | 58,054 | 54,318 | 56,334 | 61,160 | 67,631 | 73,584 | 79,200 |
| EBITDA 1 | 29,018 | 30,961 | 25,545 | 24,104 | 24,483 | 32,693 | 37,241 | 41,407 |
| EBIT 1 | 28,215 | 30,183 | 24,793 | 23,340 | 23,721 | 31,324 | 36,096 | 39,879 |
| Net income 1 | 11,542 | 11,836 | 4,863 | 4,278 | 4,226 | 13,946 | 18,968 | 22,184 |
| Net Debt 1 | 66,854 | 54,042 | 46,571 | 61,589 | 59,740 | 61,849 | 54,268 | 42,180 |
| Reference price 2 | 135.40 | 161.61 | 154.97 | 177.70 | 228.49 | 285.99 | 285.99 | 285.99 |
| Nbr of stocks (in thousands) | 1,767,880 | 1,767,880 | 1,765,537 | 1,767,140 | 1,767,385 | 1,767,117 | - | - |
| Announcement Date | 2/2/22 | 2/9/23 | 2/2/24 | 1/31/25 | 2/4/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 37.4x | 8.39x | 17.35x | 2.4% | 505B | |
| 37.84x | 13.27x | 28.43x | 0.53% | 1,148B | |
| 39.67x | 6.67x | 18.75x | 1.97% | 652B | |
| 21.45x | 5.21x | 12.93x | 2.51% | 384B | |
| 102.73x | 5.76x | 24.72x | 2.42% | 348B | |
| 21.89x | 5.76x | 13.88x | 2.85% | 294B | |
| 22.21x | 4.49x | 12.82x | 1.97% | 264B | |
| 28.66x | 7.33x | 13.12x | 2.23% | 244B | |
| -45.79x | 7.11x | 27.55x | 2.07% | 197B | |
| 11.16x | 4.11x | 8.42x | 4.5% | 168B | |
| Average | 27.72x | 6.81x | 17.80x | 2.35% | 420.54B | |
| Weighted average by Cap. | 34.32x | 8.22x | 20.15x | 1.9% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABBV Stock
- Valuation AbbVie Inc.
Select your edition
All financial news and data tailored to specific country editions
